Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large public university hospital in Sao Paulo, Brazil

Autor(es):Mostrar menos -

Luanda Mara da Silva Oliveira ^[1] ; Bruna Tiaki Tiyo ^[2] ; Lais Teodoro da Silva ^[3] ; Luiz Augusto Marcondes Fonseca ^[4] ; Rosana Coura Rocha ^[5] ; Vera Aparecida dos Santos ^[6] ; Carina Ceneviva ^[7] ; Anderson Aparecido Bedin ^[8] ; Alexandre de Almeida ^[9] ; Alberto José da Silva Duarte ; Telma Miyuki Oshiro ^[11]

Afiliação do(s) autor(es):Mostrar menos -

^[1] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[2] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[3] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[4] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[5] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[6] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[7] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[8] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[9] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

^[11] Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Revista do Instituto de Medicina Tropical de São Paulo; v. 62, 2020-11-13.

Resumo

ABSTRACT Coronavirus disease 19 (COVID-19) is caused by SARS-Cov-2 and the manifestations of this infection range from an absence of symptoms all the way up to severe disease leading to death. To estimate the prevalence of past infection in a population, the most readily available method is the detection of antibodies against the virus. This study has investigated the prevalence of anti-SARS-CoV-2 antibodies in outpatients of the Hospital das Clinicas, in Sao Paulo city (Brazil), which is a large university hospital belonging to the public health system that cares for patients with complex diseases who need tertiary or quaternary medical care. Our serological inquiry was carried out for 6 weeks, with once-a-week blood sampling and included 439 patients from several outpatient services. Overall, 61 patients tested positive for anti-SARS-CoV-2 IgG (13.9%); 56.1 % of the patients live in Sao Paulo city, with the remaining living in other towns of the metropolitan area; 32.8% of the patients testing positive for IgG antibodies to SARS-CoV-2 were asymptomatic, 55.7% developed mild or moderate disease and 11.5% had to be hospitalized. The prevalence of SARS-CoV-2 positive serology was lower among patients who had received the seasonal influenza vaccine compared to the ones who did not. These findings may indicate that those individuals care more about health issues, and/or that they have a better access to health care and/or a better quality of health care service. The large proportion of patients who were unaware of having had contact with SARS-CoV-2 deserves attention, reflecting the scarcity of tests performed in the population. (AU)

• Processo FAPESP: 19/07976-0 - Obtenção, caracterização e carregamento de vírus autólogo por células dendríticas aDC1 para imunoterapia anti-HIV
• Beneficiário: Luanda Mara da Silva Oliveira
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 16/25212-9 - Vacina terapêutica baseada em células dendríticas aDC1 e vírus autólogo inativado visando o controle viral de indivíduos infectados pelo HIV-1 em interrupção de terapia antirretroviral
• Beneficiário: Alberto José da Silva Duarte
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 18/12460-0 - Produção e caracterização de células dendríticas polarizantes aDC1 para protocolo clínico de imunoterapia anti-HIV
• Beneficiário: Laís Teodoro da Silva
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado